Xenon Pharmaceuticals Closes $747.5M Upsized Equity Offering at $57 Per Share
Xenon Pharmaceuticals closed an upsized public offering of 12,236,843 common shares, including 1,710,526 additional shares from full exercise of the underwriters’ option, plus pre-funded warrants for 877,194 common shares. The company raised approximately $747.5 million gross through $57 per share and $56.9999 per warrant offerings.
1. Offering Details
Xenon Pharmaceuticals sold 12,236,843 common shares, including 1,710,526 shares from the full exercise of the underwriters' option, and issued pre-funded warrants for 877,194 shares. The common shares were priced at $57.00 each and the pre-funded warrants at $56.9999, with an exercise price of $0.0001.
2. Proceeds and Impact
The offering generated approximately $747.5 million in gross proceeds before underwriting discounts, commissions and expenses. This capital infusion will expand the company's cash reserves and results in dilution reflecting the new share count.
3. Pipeline and Capital Use
The additional funding provides resources to advance azetukalner through Phase 3 clinical trials for epilepsy, MDD and bipolar depression, as well as early-stage potassium and sodium channel programs targeting pain. This strengthened balance sheet supports ongoing development of the neuroscience-focused pipeline.
4. Underwriters and Registration
J.P. Morgan, Jefferies, TD Cowen, Stifel, RBC Capital Markets and William Blair served as joint book-running managers, with Baird as lead manager. The securities were registered under an automatically effective shelf registration filed on August 9, 2024.